{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6787","paramType":"Hazard Ratio (HR)","paramValue":"0.90","statisticalMethod":"Stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.2","upperLimit":"92.9","value":"89.7"},{"groupId":"OG001","lowerLimit":"83.1","upperLimit":"91.4","value":"87.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"The distribution of overall survival will be estimated using the method of Kaplan-Meier. Overall survival will be compared between treatment arms using the log-rank test, only if DFS is statistically significant. The HR for OS will be estimated using a Cox proportional hazards model and the 95 percent CI for the HR will be provided. If a stratified log-rank test is used, stratified HR will be considered, and if an unstratified log-rank test is used, unstratified HR will be considered.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\n\n\\>\n\n\\> Atezolizumab: Given IV\n\n\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\n\n\\>\n\n\\> Computed Tomography: Undergo CT\n\n\\>\n\n\\> Fluorouracil: Given IV\n\n\\>\n\n\\> Leucovorin Calcium: Given IV\n\n\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\n\n\\>\n\n\\> Oxaliplatin: Given IV\n\n\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Combination Chemotherapy, Atezolizumab)"},{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\n\n\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\n\n\\>\n\n\\> Computed Tomography: Undergo CT\n\n\\>\n\n\\> Fluorouracil: Given IV\n\n\\>\n\n\\> Leucovorin Calcium: Given IV\n\n\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\n\n\\>\n\n\\> Oxaliplatin: Given IV\n\n\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Combination Chemotherapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}